This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
by Zacks Equity Research
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
by Zacks Equity Research
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
5 Broker-Loved Stocks That Hold Promise Despite Volatility
by Maharathi Basu
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
by Zacks Equity Research
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
Zacks.com featured highlights include NetApp, Installed Building Products, Ralph Lauren, Applied Materials and Cardinal Health
by Zacks Equity Research
NetApp, Installed Building Products, Ralph Lauren, Applied Materials and Cardinal Health are part of the Zacks Screen of the Week article.
Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth
by Zacks Equity Research
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.
Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva's strong product demand and strategic deals raise optimism about the stock.
GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite
by Zacks Equity Research
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
by Zacks Equity Research
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
by Zacks Equity Research
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
5 Solid Dividend Growth Stocks to Buy
by Sweta Killa
NetApp (NTAP), Installed Building (IBP), Ralph Lauren (RL), Applied Materials (AMAT), and Cardinal Health (CAH) could outperform the market this year.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
by Zacks Equity Research
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics
by Zacks Equity Research
Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.